Copper GHK-Cu 1:1

What is GHK-Cu?

GHK-Cu is a synthetic copper-binding tripeptide consisting of the amino acid sequence glycine-histidine-lysine (GHK) chelated to a copper(II) ion in a 1:1 molar ratio. The parent tripeptide GHK was first isolated from human plasma in 1973 by Pickart and Thaler, and has since been characterised as an endogenous signalling molecule detectable in plasma, saliva, and urine across multiple mammalian species. In human plasma, GHK has been detected at concentrations of approximately 200 ng/mL in younger adults, with levels declining to approximately 80 ng/mL by age 60. In chelated form as GHK-Cu, the compound has been investigated in preclinical and in vitro research contexts for its interactions with cellular repair signalling networks, extracellular matrix (ECM) dynamics, and copper-dependent enzymatic pathways.

GHK-Cu is classified as a research-grade synthetic peptide. It is not approved by the Food and Drug Administration for human or veterinary use, is not a dietary supplement, and is not intended for human consumption or therapeutic application. All RCDbio research compounds are supplied strictly for laboratory and research purposes only.

Chemical Properties

How Does GHK-Cu Work?

GHK-Cu has been investigated in preclinical and in vitro systems for interactions across several molecular pathways. The copper coordination is considered mechanistically relevant, as the copper(II) ion influences the compound's interaction profile with cellular receptor systems and metalloenzyme cascades.

Extracellular Matrix Modulation Pathway

In fibroblast and keratinocyte cell culture models, GHK-Cu has been investigated for its capacity to modulate gene expression associated with ECM remodelling. Studies in isolated cell systems have observed upregulation of collagen types I and III gene expression following GHK-Cu exposure [Pickart & Margolina, 2018]. Simultaneously, data from in vitro preparations suggest interactions with matrix metalloproteinase (MMP) regulatory networks — specifically, observations of modulated MMP-1 and MMP-2 activity in dermal fibroblast models [Pickart et al., 2015], though findings are not consistent across all preparations and concentration ranges. Glycosaminoglycan and decorin synthesis have also been investigated in isolated fibroblast systems in the context of broader ECM remodelling research.

Copper-Dependent Superoxide Dismutase (SOD) Pathway

GHK-Cu has been investigated as a copper chaperone in isolated cell preparations. Mechanistically, the compound has been observed to facilitate intracellular copper delivery to copper-dependent enzymes, including superoxide dismutase 1 (SOD1), in cell-free and cell-based assay systems [Pickart & Margolina, 2018]. These observations are derived from in vitro conditions; whether analogous copper trafficking occurs in intact tissue is not established.

Growth Factor Signalling Interactions

In preclinical models, GHK-Cu has been investigated for interactions with TGF-β1 (transforming growth factor-beta 1) and VEGF (vascular endothelial growth factor) signalling. Data from isolated cell preparations suggests GHK-Cu exposure may be associated with modulation of these growth factor pathways in fibroblast and endothelial cell systems [Pickart et al., 2015]. Findings indicate increased expression of relevant downstream markers in some models; however, data remains limited and is not uniform across experimental systems.

Proteasome Activation in Isolated Systems

In vitro investigations have examined GHK-Cu in the context of ubiquitin-proteasome system (UPS) activity. Laboratory data suggest the compound may interact with proteasomal function in isolated neuronal cell preparations, with observations reported in the context of cellular stress models. These findings are early-stage and have not been replicated across all experimental conditions.

Key Research Findings

In preclinical and in vitro research contexts, GHK-Cu has been associated with the following observations:

• ECM gene expression: Upregulation of collagen I and III gene expression observed in isolated dermal fibroblast preparations following GHK-Cu exposure in cell culture systems [Pickart & Margolina, 2018].
• MMP modulation: Altered MMP-1 and MMP-2 activity levels observed in in vitro dermal fibroblast models; findings not consistent across all concentration ranges tested [Pickart et al., 2015].
• Growth factor pathway interaction: Modulation of TGF-β1 and VEGF signalling markers observed in fibroblast and endothelial cell models in controlled laboratory settings [Pickart et al., 2015].
• Copper delivery: GHK-Cu characterised as a copper(II) chaperone in cell-free and cell-based assay systems, with observations of copper delivery to SOD1 in isolated preparations.
• Antioxidant enzyme context: Data from in vitro oxidative stress models suggest GHK-Cu exposure is associated with altered superoxide dismutase activity in isolated cell systems.

All findings listed above are derived from preclinical or in vitro data. No human clinical trial data have been established for GHK-Cu. These observations do not constitute evidence of efficacy or safety in any human condition or organism.

What are the Potential Research Applications of GHK-Cu?

In controlled laboratory environments, GHK-Cu has been investigated for the following research applications. These are observed in preclinical and in vitro contexts only and do not constitute claims of efficacy or safety in any organism.

Extracellular Matrix and Fibroblast Signalling Studies: GHK-Cu has been employed as a reference compound in studies characterising fibroblast responses to copper-binding peptide exposure. Investigations have examined collagen gene expression dynamics, MMP regulation, glycosaminoglycan synthesis, and ECM remodelling marker profiles in isolated cell systems.

Copper Chaperone and Metalloenzyme Research. The compound has been investigated as a model copper(II) delivery agent in cell-free and cell-based assay systems designed to study intracellular copper trafficking and its relationship to metalloenzyme activity, including SOD1 and ceruloplasmin-related pathways.

Growth Factor Pathway Interaction Studies. In vitro cell models have employed GHK-Cu to study its interactions with TGF-β and VEGF signalling cascades in fibroblast, keratinocyte, and endothelial cell preparations. These investigations have examined downstream transcriptional markers associated with cellular proliferation and migration under controlled laboratory conditions.

Oxidative Stress Model Research. GHK-Cu has been investigated in in vitro oxidative stress assay systems as part of research into copper-peptide complex behaviour under reactive oxygen species (ROS)-generating conditions, including its interaction with antioxidant enzyme expression profiles in isolated cell preparations.

Structure-Activity Relationship (SAR) Studies. The compound serves as the reference standard in SAR investigations examining how copper coordination geometry, molar stoichiometry (1:1 vs. 2:1), and peptide sequence modifications alter interaction profiles with cellular targets in transfected cell systems and receptor binding assays.

What are the Potential Side Effects of GHK-Cu?

Researchers in preclinical and in vitro settings have noted the following observations. Long-term safety and toxicity profiles remain incompletely characterised, and no human safety data have been established.

• Cytotoxicity observed at supraphysiological concentrations in isolated fibroblast and keratinocyte cell preparations; not consistently observed at concentrations used in standard research protocols
• Disruption of intracellular copper homeostasis has been reported in cell-free systems at elevated molar concentrations; the mechanistic basis has not been fully characterised
• Modulation of MMP activity observed in vitro, with implications for ECM research models at higher concentration ranges
• Interference with endogenous copper-binding protein interactions is possible in cell-based systems at concentrations above typical research ranges
• Copper ion-mediated pro-oxidant effects noted in isolated cell preparations under specific oxidative stress conditions; findings are model-dependent and not replicated uniformly

No human safety or tolerability data have been established for GHK-Cu. These observations are derived from experimental systems and should not be extrapolated to human or animal outcomes.

Risk & Handling

Handling Precautions

GHK-Cu should only be handled by trained laboratory personnel familiar with peptide research compounds. Appropriate personal protective equipment is required: nitrile gloves, a laboratory coat, and eye protection at a minimum. When working with the lyophilized powder, use within a fume hood or laminar flow cabinet to avoid inhalation of particulate matter. Avoid aerosol generation during reconstitution. The compound's blue-green colouration at higher concentrations may stain surfaces and porous materials.

Exposure Risks

Risk Tier: LOW–MODERATE

GHK-Cu has demonstrated a generally low acute toxicity profile in rodent preclinical studies at concentrations relevant to standard laboratory research protocols. Cytotoxic effects have been observed in isolated cell preparations at supraphysiological concentrations. Copper ion release from the chelate complex under certain pH conditions introduces a secondary risk consideration in cell-based research systems. No human safety or tolerability data have been established for GHK-Cu. Researchers should exercise appropriate caution consistent with handling any bioactive copper-containing compound.

Storage

• Lyophilized form: Store at −20°C in original sealed, light-protected container with desiccant
• Reconstituted form: Store at 4°C; use within 48–72 hours of reconstitution
• Do not subject to repeated freeze-thaw cycles; peptide integrity may be compromised with each cycle
• Protect from prolonged light exposure; the copper complex is photosensitive at higher concentrations
• Store away from strong oxidising agents and chelating chemicals that may disrupt copper coordination

Frequently Asked Questions

Q: What is GHK-Cu, and what is it investigated for in research? GHK-Cu is a copper(II)-chelated tripeptide (glycine-histidine-lysine) in a 1:1 molar ratio, investigated in preclinical and in vitro research contexts for its interactions with extracellular matrix signalling, copper-dependent enzymatic pathways, and growth factor modulation in isolated cell systems. It is not approved by the FDA for human use and is intended strictly for laboratory and research purposes.

Q: What is the half-life of GHK-Cu in vitro? In plasma-based in vitro studies, GHK has been reported to have a half-life of approximately 0.5 to 1 hour, based on preclinical degradation data. Stability is influenced by pH, temperature, and the presence of competing metal ions in the experimental environment. These figures are derived from laboratory models and do not represent human pharmacokinetic data.

Q: How should GHK-Cu be stored to maintain stability? Lyophilized GHK-Cu should be stored at −20°C in a sealed, light-protected container with desiccant. Once reconstituted, the working solution should be stored at 4°C and used within 48–72 hours. Repeated freeze-thaw cycles are not recommended, as they may degrade peptide integrity and disrupt copper coordination. Protect from prolonged light exposure and avoid contact with competing chelating agents.

Q: What are the known toxicity observations for GHK-Cu in preclinical studies? Preclinical studies in rodent models and isolated cell preparations have reported a generally low acute toxicity profile for GHK-Cu at concentrations investigated in standard research protocols. Cytotoxicity has been noted at supraphysiological concentrations in isolated fibroblast and keratinocyte cell systems. No human safety or tolerability data have been established for GHK-Cu. These observations are model-specific and should not be extrapolated to human or animal outcomes.

Q: What is GHK-Cu typically reconstituted with in laboratory research? In laboratory settings, GHK-Cu is commonly reconstituted in sterile water or phosphate-buffered saline (PBS) to produce working stock solutions. Reconstitution should be carried out by trained laboratory personnel under aseptic conditions. The compound's solubility in aqueous media makes it compatible with standard cell culture buffers at typical research concentrations.

Q: Does GHK-Cu require copper chelation for its observed in vitro activity? Research indicates that copper coordination is integral to the observed bioactivity of GHK-Cu in in vitro systems. Studies in cell-free and isolated cell preparations suggest the copper-peptide complex mediates receptor and signalling interactions not consistently observed with the free tripeptide (GHK) alone. Findings are not uniform across all experimental models, and data remain limited regarding the precise role of copper coordination geometry in modulating activity profiles.

Q: What is the difference between GHK-Cu 1:1 and GHK-Cu 2:1? GHK-Cu 1:1 is a single defined compound with one GHK tripeptide chelated to one copper(II) ion, with approximately 14% copper content by mass. GHK-Cu 2:1 is a mixture of free GHK and GHK-Cu 1:1, resulting in a 2:1 molar ratio of peptide to copper and approximately 7% copper content. No peer-reviewed literature has established functional differences between the two forms in preclinical research models; choice between them in laboratory settings is typically driven by formulation requirements and copper reactivity considerations. Visit RCD Bio to explore our full research compound catalog.